GSK shares tumble by most in two years after Zantac ruling
GSK shares tumble by most in two years after Zantac ruling
GSK shares dropped by the most in nearly two years after a ruling by the Delaware State Court that will allow jury trials in cases brought by cancer sufferers who say the heartburn drug Zantac caused their condition.
